Track topics on Twitter Track topics that are important to you
DeuteRx LLC granted Poxel SA exclusive global rights to DRX065, a Phase I candidate that Poxel intends to develop for nonalcoholic steatohepatitis (NASH).
Poxel has completed patient enrolment for the TIMES 1 trial in Japan to investigate the use of Imeglimin for the...Read More... The post Poxel completes enrolment in TIMES 1 trial appeared first on Dr...
Poxel has initiated the second part of the Phase Ia study of PXL065, which is being developed for the treatment...Read More... The post Poxel initiates second part of PXL065 study to treat NASH appear...
French biopharmaceutical firm Poxel has concluded patient enrolment in the Phase III TIMES 2 clinical trial of its drug candidate...Read More... The post Poxel closes enrolment in TIMES 2 trial of Ime...
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non─alcoholic steatohepatitis (NASH), has announced f...
Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel...
Biohaven Therapeutics has signed a licensing agreement with AstraZeneca for a new drug candidate, AZD3241, targeting a rare neurodegenerative disease....Read More... The post Deals this week: Biohaven...
This second part of the Phase 1a study will enroll six healthy subjects per group, with a primary objective to assess safety and tolerability and a secondary objective The post Poxel begins part 2 of...
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A of ...
Poxel is a new RIPCO that aims to advance promising assets for cardio-metabolic diseases from Research to Phase 2 Clinical Proof of Concept, before out licensing projects to pharmaceutical compani...
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alco...
We have published hundreds of POXEL S.A. news stories on BioPortfolio along with dozens of POXEL S.A. Clinical Trials and PubMed Articles about POXEL S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of POXEL S.A. Companies in our database. You can also find out about relevant POXEL S.A. Drugs and Medications on this site too.